Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Stomach-Derived peptide help tendons heal faster after surgery?

NCT ID NCT07803250

Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether BPC-157, a synthetic peptide, can improve tendon healing and strength after rotator cuff repair surgery. About 20 adults with a full-thickness rotator cuff tear will receive either BPC-157 or a placebo injection daily for 90 days after their operation. Researchers will measure shoulder strength, range of motion, and MRI evidence of tendon healing, along with blood markers of inflammation and collagen turnover. The goal is to see if BPC-157 is safe and worth testing in a larger study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BPC-157, a synthetic peptide derived from human gastric juice, given as daily subcutaneous injections for 90 days after surgery.
What this could lead to
If BPC-157 improves tendon healing and strength, it could become a treatment to speed recovery after rotator cuff surgery and reduce the need for revision procedures.
What could go wrong
This is a small early-stage pilot study, and BPC-157 has not been tested in formal human trials before. It may not improve outcomes, and its safety in humans is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and Females, 18 years old or older * Body mass index of 20.0 to 34.9 kg/m2 * Pre-operative MRI demonstrating a full thickness tear of the posterosuperior rotator cuff less than 2.5 cm in anteroposterior dimension * Scheduled for an aRCR at UAMS with Dr. Ryan Hill, Dr. Paul Inclan, or Dr. Justin Rabinowitz * COVID-19 negative and/or asymptomatic Exclusion Criteria: * Previous RCR * Pregnant or breastfeeding status * Current drug and alcohol abuse · History of platelet-rich plasma injection, other platelet-based product or biologic injection in the past 12 months in the ipsilateral shoulder * Lack of decisional capacity * Having undergone hormone replacement therapy in the last 12 months * Having undergone testosterone replacement therapy in the last 12 months * Active diagnosis of blood borne infectious disease * Diabetic * Documented history or diagnosis of autoimmune disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rotator cuff tear are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rotator Cuff Injuries rotator cuff syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rotator cuff tear

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Arkansas for Medical Sciences Medical Center

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.